Abstract: The invention relates to derivatives of 4,4?-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.

Abstract: An object of the present invention is the use of at least one inhibitor of angiogenesis consisting of AGT or derivatives thereof in the manufacture of a drug for treating pathologies or disorders notably angiogenesis-dependent or mediated pathologies generally characterised by excessive angiogenesis. The present invention also relates to a cell transfected with at least one expression vector wherein said expression vector hosts a recombinant nucleic acid encoding an AGT or one of its derivatives for use in therapy of angiogenesis-mediated pathologies. The present invention further relates to an expression vector for use in said cell.

Abstract: The invention relates to the bis-hydrochloride of 4,4?-dithiobis-(3-aminobutane-1-sodium sulphonate) and the bis-trifluoracetate of 4,4?-dithiobis-(3-aminobutane-1-sulphonate of 2,2-dimethylpropyl). The invention also relates to a pharmaceutical composition comprising one of said compounds and to the use of one of said compounds for the production of a medicament. The invention is suitable for use in a treatment method for hypertension and indirectly- or directly-linked illnesses.

Abstract: The invention relates to derivatives of 4,4?-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.

Abstract: The invention relates to the bis-hydrochloride of 4,4?-dithiobis-(3-aminobutane-1-sodium sulphonate) and the bis-trifluoracetate of 4,4?-dithiobis-(3-aminobutane-1-sulphonate of 2,2-dimethylpropyl). The invention also relates to a pharmaceutical composition comprising one of said compounds and to the use of one of said compounds for the production of a medicament. The invention is suitable for use in a treatment method for hypertension and indirectly- or directly-linked illnesses.

Abstract: An object of the present invention is the use of at least one inhibitor of angiogenesis consisting of AGT or derivatives thereof in the manufacture of a drug for treating pathologies or disorders notably angiogenesis-dependent or mediated pathologies generally characterised by excessive angiogenesis. The present invention also relates to a cell transfected with at least one expression vector wherein said expression vector hosts a recombinant nucleic acid encoding an AGT or one of its derivatives for use in therapy of angiogenesis-mediated pathologies. The present invention further relates to an expression vector for use in said cell.

Abstract: The invention relates to peptide derivatives that can be used as selective inhibitors of the N-terminal site of human angiotensin-converting enzyme. The derivatives comprise the amino acid sequence with the following formula: -Asp-Phe-&PSgr;(PO2CH2)-Ala-Xaa′-  (I) wherein: &PSgr;(PO2CH2) indicates that the peptide bond (CONH) between Phe and Ala has been replaced by the phosphonic bond PO2CH2, and Xaa′ represents an amino acid residue. They can be used in pharmaceutical formulations, particularly to protect haematopoietic strain cells of patients undergoing aggressive chemotherapy or radiotherapy treatment.

Abstract: The invention relates primarily to a pharmaceutical composition which can be used for lowering arterial blood pressure and is characterized in that it contains as active ingredient at least one selective aminopeptidase A inhibitor. Said inhibitor can notably be (S) 3-amino-4-mercaptobutyl sulfonic acid or one of its salts.

Abstract: The association of the molecular variant G-6A of the angiotensinogen gene with human hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood presure.

Abstract: The association of the molecular variant G-6A of the angiotensinogen gene with human hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood pressure.

Abstract: The association of the molecular variant G-6A of the angiotensinogen gene with human hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood presure.

Abstract: The invention discloses a method for detecting polymorphism in the angiotensin converting enzyme by means of a chain amplification technique, the aim being to detect whether or not the sequence of nucleotides 1451-1738 of intron 16 is present in the human angiotensin converting enzyme gene.

Abstract: The association of molecular variants of the angiotensinogen gene with human essential hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood presure.

Abstract: The invention relates to the cloning and sequencing of the nucleic acid coding for the human ACE as well as the determination of the peptide chain corresponding to the ACE and of active peptide fragments which derive from it.Another subject of the invention is the utilization of the above-mentioned polypeptides for the implementation of in vitro diagnostic methods for hypertension and for the design of new inhibitors of the ACE.The invention also relates to the utilization of the nucleotide probes of the invention for the in vitro screening of the polymorphisms of the gene coding for the ACE.

Abstract: The invention relates to the cloning and sequencing of the nucleic acid coding for the human ACE as well as the determination of the peptide chain corresponding to the ACE and of active peptide fragments which derive from it.Another subject of the invention is the utilization of the above-mentioned polypeptides for the implementation of in vitro diagnostic methods for hypertension and for the design of new inhibitors of the ACE.The invention also relates to the utilization of the nucleotide probes of the invention for the in vitro screening of the polymorphisms of the gene coding for the ACE.

Abstract: The present invention relates to peptide derivatives of the general formula:R--X--Y--Statyl.sub.1 --Ala--Statyl.sub.2 --R' (1),in which:Statyl.sub.1 and Statyl.sub.2 represent the radical derived from the aminoacid statine,R denotes a hydrogen atom or an acylating group attached to the terminal amino group of the aminoacid X--,X and Y, which are identical or different, denote aminoacids of the L or D configuration if a center of asymmetry exists in the molecule, and optionally protected in their side chain, with the proviso that X and Y cannot simultaneously denote valine, andR' denotes OH, O-lower alkyl, NH.sub.2 or a group NH-R.sub.1, in which R.sub.1 represents a lower alkyl or lower aralkyl group.It also relates to a process for the preparation of the products of the formula (1) and to the medicaments containing a product of the formula (1) as the active principle.

Abstract: The novel derivatives of pepstatin have the general formula (I) below in which X, Y and Z, are identical or different, and each represent an amino-acid selected from arginine, glutamic acid, aspartic acid, lysine, histidine and valine, the carboxyl function of the terminal amino-acid being esterifiable. The indices a, b and c are each equal to zero or 1, the sum a+b+c being equal to 1, 2 or 3. The invention also includes the water soluble salts and their preparation, and the compositions containing them. ##STR1## These novel products are particularly useful in the diagnosis and treatment of arterial hypertension due to the action of renine.